Clinical Trials Browser

Recruiting × INDUSTRY × Neoplasms, Plasma Cell × Clear all

NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07529782 2026-04-14

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04271644 2025-02-25

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04776330 2025-02-25

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06271252 2024-08-02

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Phase 1 Recruiting

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT04879043 2024-07-24

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell